The 2-NBDG signal appears higher in the Her2+ primary tumor compared to the regressing, dormant, and recurrent tumors in Fig. 1c, suggesting a decrease in glycolytic activity following Her2 downregulation. This evidence concerns the gene ERBB2 and neoplasm.